Improved Antitumor Activity of Interleukin-12-Secreting Chimeric Antigen Receptor T Cells Targeting CD176 across Different Carcinomas
Overall, the IL-12 release substantially improved effector functionality against CD176<sup>+</sup> cells but not CD176<sup>-</sup> cells, indicating efficacy while maintaining specificity. Thus, CD176-iIL12-TRUCKs, with their potent antitumor efficacy and TME modulation potential, are a promising treatment option for patients with a variety of advanced solid tumors.
Authors
- Rainer Blasczyk (ORCID: https://orcid.org/0000-0003-3875-3190)
- Anna Christina Dragon (ORCID: https://orcid.org/0000-0002-5228-7627)
- Britta Eiz‐Vesper (ORCID: https://orcid.org/0000-0001-8378-3298)
- Axel Schambach (ORCID: https://orcid.org/0000-0003-2743-0070)
- Agnes Bonifacius (ORCID: https://orcid.org/0000-0002-0112-967X)
- Hinrich Abken (ORCID: https://orcid.org/0000-0002-4302-3240)
- Johanna Gellert (ORCID: https://orcid.org/0009-0005-9518-9137)
- Patrik Kehler (ORCID: https://orcid.org/0009-0004-4557-059X)
- Michael Hudecek (ORCID: https://orcid.org/0000-0002-2280-2202)
- Luca Marie Beermann
- Melina Umland (ORCID: https://orcid.org/0009-0002-9151-9184)
Institutions
- University Hospital Regensburg (DE)
- Medizinische Hochschule Hannover (DE)
- Glycotope (Germany) (DE)
- Universitätsklinikum Würzburg (DE)
Publication Details
- Journal
- Transfusion Medicine and Hemotherapy
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1159/000549632
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Medizinischen Hochschule Hannover
- Deutsche Krebshilfe
- Deutsche Kinderkrebsstiftung